Allurion Technologies (ALUR) said Thursday that initial trial results from the Allurion balloon in combination with semaglutide showed total body weight loss and lean body mass gains.
The company treated 52 patients in the study and the average total body weight loss was 20.3% after eight months while the lean body mass increased by 15%, according to the company.
Shares of the company were up 29% in recent after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.